Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

VC Roundup: October Brings Several New Venture Funds, Including Third Rock’s Fourth

Nov 01 2016

• By Mandy Jackson

Related Content

Biotech IPO Window Closed In November As Returns And Prices Plunged

Dec 03 2015

Biotech Stars And Startups Raise $168m In Venture Cash

Dec 03 2015

VC Funding: Increasing Prior Rounds; New Strategy In Lieu Of An IPO?

Mar 30 2016

Sage Drug Could Help Take Stigma Out Of Postpartum Depression

Jul 14 2016

Five promising approaches to expand the depression armory

Oct 17 2014

‘Open Science’ In Action: Allergan Exercises Option For Motus After Gastroparesis Study

Oct 28 2016

VC Roundup: Early-Stage Funding Slips Again In Third Quarter, Plus 15 New Financings

Oct 08 2016

Helsinn Family Business Establishes $50m Start-Up Investment Fund

Oct 10 2016

Can Editas, BeiGene Offerings Redeem US IPO Class Of 2015?

Feb 04 2016

Patient Registries Prove Value As Drug Development Tools

Apr 19 2016

Viventia's Cancer Ambitions Go To Eleven

Sep 21 2016

Third Rock raises $516m for early-stage venture deals

Mar 26 2013

Related Companies

Helsinn Healthcare SA

Foundation Medicine, Inc.

Allergan plc

Rhythm Pharmaceuticals, Inc.

Sage Therapeutics, Inc.

Editas Medicine

Voyager Therapeutics, Inc

Sesen Bio, Inc.

UNITY Biotechnology, Inc.

True North Therapeutics, Inc.

BlackThorn Therapeutics, Inc.

Eli Lilly and Company

EMulate Therapeutics, Inc.

Mavalon Therapeutics Ltd.

Domain Therapeutics S.A.

Additional Topics

Financing StartUps and SMEs Commercial BioPharmaceutical

More from Financing

More from Business

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window